Drugs that contain Mipomersen Sodium
1. List of Kynamro drug patents
KYNAMRO Litigations
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(2 months ago) | |
| US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(3 months from now) | |
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(3 years from now) | |
Do you want to check out KYNAMRO patents from before 2022?
Market Authorisation Date: 29 January, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
KYNAMRO family patents
19
United States
11
Japan
6
European Union
3
Spain
3
Cyprus
3
Portugal
3
Australia
3
Denmark
2
Canada
2
Slovenia
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic